ERBB2 and breast carcinoma: Interestingly, in the cases harboring TP53 somatic mutations analyzed here, these mutations were found to be likely founder genetic events, potentially preceding the amplification of HER2, in a way akin to the TP53 germline mutations preceding HER2 amplification in breast cancers from Li-Fraumeni patients.